Skip to main content
3SBio Inc. logo

3SBio Inc. — Investor Relations & Filings

Ticker · 1530 ISIN · KYG8875G1029 LEI · 529900P0TQC1E9Y7FN31 HKEX Manufacturing
Open in API
Filings indexed 1,492 across all filing types
Latest filing 2016-03-16 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1530

About 3SBio Inc.

http://www.3sbio.com

3SBio Inc. is a biopharmaceutical enterprise specializing in the integrated research, development, production, and commercialization of innovative biopharmaceutical products. The company operates as a biotechnology firm, focusing on the discovery, development, manufacture, and marketing of biologics, with a particular emphasis on mammalian cell-based biopharmaceuticals. 3SBio addresses critical medical needs by providing an extensive range of products and services to markets both domestically and internationally.

Recent filings

Filing Released Lang Actions
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from 3SBio Inc. regarding a scheduled board meeting to consider and approve the annual results for the year ended December 31, 2015, and the payment of a final dividend. It does not contain any actual financial data or the results themselves, only a notice of the meeting. The document length is only 1394 characters, which is quite short and consistent with an announcement rather than a full report. According to the MENU VS MEAL RULE, this is an announcement about the upcoming report and dividend decision, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2016-03-16 English
JOINT ANNOUNCEMENT - DISCLOSEABLE TRANSACTION - Undertakings in relation to OUE H-Trust Rights Issue and Exchangeable Loans to joint ventures
Capital/Financing Update Classification · 95% confidence The document is a joint announcement by Lippo Limited and Hongkong Chinese Limited regarding a discloseable transaction related to undertakings in relation to a rights issue and exchangeable loans to joint ventures. It discusses the terms of the transaction, the parties involved, the financial commitments, and the regulatory implications under the Listing Rules. The document is an announcement of a transaction and not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but rather describes the transaction details and compliance with listing rules. Therefore, it fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2016-03-07 English
CONNECTED TRANSACTION AND MAJOR TRANSACTION IN RELATION TO THE ACQUISITION OF FURTHER EQUITY INTERESTS IN SHANGHAI CP GUOJIAN PHARMACEUTICAL CO. LTD. AND PROPOSED GRANT OF OPTIONS - UPDATE
Capital/Financing Update Classification · 95% confidence The document is an announcement related to a connected and major transaction involving the acquisition of further equity interests and the proposed grant of options. It provides details about the exercise price of options and references a previous announcement and upcoming circular to shareholders. The content focuses on transaction details and shareholder communication rather than financial results, management changes, or regulatory certifications. The document is relatively short (3533 characters) and is clearly an announcement of a transaction update rather than a full report or detailed financial disclosure. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2016-03-07 English
(1) CONNECTED TRANSACTION AND MAJOR TRANSACTION IN RELATION TO THE ACQUISITION OF FURTHER EQUITY INTERESTS IN SHANGHAI CP GUOJIAN PHARMACEUTICAL CO., LTD AND PROPOSED GRANT OF OPTIONS AND (2) CLARIFI
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from 3SBIO Inc. regarding a connected transaction and major transaction related to the acquisition of further equity interests in a subsidiary company. It includes specifics about agreements, consideration, parties involved, regulatory compliance with the Hong Kong Stock Exchange Listing Rules, and shareholder approval processes. The content focuses on transaction details, regulatory implications, and shareholder approvals rather than financial results or earnings. It is not a full financial report, earnings release, or management discussion. The document is an announcement of a corporate transaction and related regulatory compliance, fitting the category of Capital/Financing Update (CAP).
2016-03-07 English
CONNECTED TRANSACTION AND MAJOR TRANSACTION IN RELATION TO THE ACQUISITION OF FURTHER EQUITY INTERESTS IN SHANGHAI CP GUOJIAN PHARMACEUTICAL CO. LTD. AND PROPOSED GRANT OF OPTIONS - UPDATE
Capital/Financing Update Classification · 95% confidence The document is an announcement from 3SBio Inc. regarding a connected and major transaction related to the acquisition of further equity interests and the proposed grant of options. It provides details about the exercise price of the options and references a previous announcement and upcoming circular to shareholders. The document is relatively short (3533 characters) and focuses on transaction details rather than financial results or comprehensive reports. It does not contain financial statements or detailed analysis but is an update on a capital transaction. Therefore, it fits best under Capital/Financing Update (CAP).
2016-03-04 English
(1) CONNECTED TRANSACTION AND MAJOR TRANSACTION IN RELATION TO THE ACQUISITION OF FURTHER EQUITY INTERESTS IN SHANGHAI CP GUOJIAN PHARMACEUTICAL CO., LTD AND PROPOSED GRANT OF OPTIONS AND (2) CLARIFI
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from 3SBIO Inc. regarding a connected transaction and major transaction related to the acquisition of further equity interests in a subsidiary company. It discusses agreements, consideration, regulatory compliance under the Hong Kong Stock Exchange Listing Rules, shareholder approvals, and related corporate actions. The content focuses on transaction details, regulatory implications, shareholder approvals, and clarifications about connected transactions. There is no indication that this is a full financial report, earnings release, or management discussion. It is not a proxy solicitation or voting results announcement, nor is it a remuneration or audit report. The document is a formal announcement of a major corporate transaction and related regulatory compliance, which fits the category of Capital/Financing Update (CAP). The length and detail confirm it is not a brief announcement or a report publication notice. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2016-03-03 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.